Rozbor firmy
Johnson & Johnson (JNJ): pharmaceuticals and medical devices as a portfolio cornerstone?
Key takeaways
- After spinning off the consumer division (Kenvue), JNJ focuses exclusively on prescription drugs and medical devices.
- The company's moat is formed by patents on blockbuster drugs, an extensive salesforce and regulatory expertise with the FDA.
- JNJ is a dividend aristocrat — it has raised its dividend consistently for decades.
- Key risks are patent cliffs (expiries) and litigation relating to legacy products.
- Healthcare ETFs (XDWH) offer exposure to JNJ alongside other pharmaceutical names.
Johnson & Johnson (JNJ) is one of the world's best-known healthcare companies — after spinning off the consumer business (Kenvue) it now focuses on innovative medicines and medical devices.
What JNJ does today
The business rests on two pillars. Innovative Medicine (formerly Janssen) develops and sells prescription drugs in oncology, immunology and neuroscience — including blockbusters such as Darzalex, Stelara and Tremfya. MedTech manufactures surgical robotics systems (Ottava in development), orthopaedic implants and instruments for minimally invasive surgery.
Economic moat
JNJ is protected by several layers. Patents on key drugs grant temporary monopolies; a large salesforce enables faster market launches than smaller rivals; and regulatory know-how in working with the FDA reduces the risk of new molecules failing approval. The MedTech division benefits from a strong brand in hospitals and switching costs when replacing equipment.
Risks and where to be cautious
- Patent cliff: Stelara was losing protection — biosimilars are attacking its market share; watch what in the pipeline replaces that decline.
- Litigation: the historical talc lawsuit (baby powder) demonstrated that legal risks are real; the company addressed them through the Kenvue spin-off.
- Drug price regulation: political pressure to lower drug prices in the US is a long-term margin risk.
Investment thesis and ETF approach
JNJ is a typically defensive name with a dividend history spanning decades. It belongs among dividend aristocrats — companies that raise their payout consistently. Investors seeking indirect exposure can turn to a healthcare ETF (e.g. XDWH), where JNJ is a natural constituent. A fund overview is available in the ETF overview.
FAQ
What happened to Kenvue and why did JNJ spin it off?
Kenvue is JNJ's former consumer division (Tylenol, Band-Aid, Neutrogena). JNJ spun it off to concentrate on innovative medicines and medical devices with higher margins. Kenvue is now a separately traded company.
Is JNJ suitable for a conservative investor?
Relatively yes — stable dividends, defensive sector. But patent expiries and regulatory risks are real. For a conservative investor, a sector ETF may be wiser than a single stock.
How to invest in JNJ via ETF from the Czech Republic?
ETFs such as XDWH (healthcare sector) or global dividend funds (VHYL, ZPRG) typically hold JNJ. They are purchased through a broker with exchange access — see the broker overview.